BioStem Technologies Inc. (OTC:BSEM) Stock In Focus After Latest Development
The medical technology leader BioStem Technologies Inc. (OTC:BSEM) is involved in the manufacturing, development, and commercialization of biologics derived from placenta for advanced wound care.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
On Wednesday, the stock came on to the radars of investors after the company announced the commencement of the BioREtain-AAmnion Chorion-DDiabetic Foot Ulcers (BR-AC-DFU-101) clinical trial in order to evaluate BioREtain-AAmnion Chorion (BR-AC) in comparison to the standard treatments provided to patients suffering from non-healing DFUs (diabetic foot ulcers). The study would look into a patient population consisting of DFU with suitable perfusion but without the symptoms and clinical signs of infection.
In the news release, BioStem Technologies stated that it would enroll a total of 60 patients suffering from non-healing DFUs spread across 10 sites in the United States. The company went on to note that the study would be concluded by the end of 2025. There would also be subject visits on a weekly basis in order to keep track of compliance with wound care as well as offloading.
The monitoring would also help in accurately recording the time of wound closure. The announcement created strong interest in the BioStem Technologies stock yesterday, and it may be a good time to add the stock to your watch lists.
CEO Comment
Jason Matuszewski, CEO of BioStem Technologies, commented: “We are excited to initiate the BR-AC-DFU-101 clinical trial, which aims to potentially demonstrate the clinical significance of our proprietary BioREtain technology against the standard of care. We believe the findings from this trial will enhance the understanding of the healing benefits of our products and pave the way for broader insurance coverage and market acceptance. BioStem is focused on driving revenue growth through improving the payer network for our products to build on the record revenue of more than $100 million we reported in the first half of 2024. Our patented BioREtain process is the technology utilized in our products and will be a key differentiator for BioStem’s commercial products going forward. Ultimately, we aim to better address the needs of patients suffering from non-healing diabetic foot ulcers and improve their quality of life. We are confident that the results will highlight the strength of our technology and provide substantial benefits to support BioStem and its shareholders as the company advances.”
Key Fundamentals
| P/E Ratio | 29.33 |
| PEG Ratio | 0.16 |
| Price to Book | 10.64 |
| Price to Cash Flow | 36.9405 |
| Price to Free Cash Flow | 39.4549 |
| Total Sales (TTM) | 131.44 M |
| Revenue per Share (TTM) | 6.28 |
| Shares Outstanding | 16.227 M |
| Share Float (%) | 11.74 M (72.36%) |